17-Estradiol (E 2 ) accelerates reendothelialization and increases the number of circulating endothelial progenitor cells (EPCs), but whether fibroblast growth factor-2 (FGF2) is involved in these processesEndothelium, uniquely positioned at the interface between the blood and the vessel wall, plays a crucial role in the physiology of circulation by performing multiple functions.1 It is involved in the regulation of coagulation, leukocyte adhesion in inflammation, transvascular flux of cells, liquids and solutes, vessel tone, and vascular smooth muscle growth. Endothelium also constitutes a target for the sex hormone 17-estradiol (E 2 ). In a series of experimental models, E 2 has been reported to promote endothelial regrowth after endothelial denudation in rats 2 and mice.3-5 These effects are known to be mediated through the estrogen receptor ␣ 3 and endothelial nitricoxide synthase. 4 Several growth factors could be involved in this process. Among them, in vitro models suggest that fibroblast growth factor-2 (FGF2) may be a key partner of E 2 . 6,7 Moreover, both FGF2 and FGF receptor 1 are expressed in regenerating endothelial cells in a model of rat carotid injury, 8 and FGF2 is an important mitogenic and angiogenic factor that stimulates endothelial cell growth, migration, and reendothelialization. 9 FGF2 expression is complex because at least four isoforms (18, 22, 22.5, and 24 kd) in humans and three (18, 21, and 22 kd) in mice are synthesized, not through the classic mechanism of